PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis

Bao, Wen-Dai; Kong, Rui; Wang, Nan; Han, Wei; Lü, Jie

doi:10.1155/2021/6629455

Cited by 9 publications

(5 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[45] Notably, hyperlipidemia is an important cause of AP. [46,47] Eisenbergiella bacteria exhibit pathogenic properties in some inflammatory diseases. [48,49] However, its role in AP has not been studied.…”

Section: Discussionmentioning

confidence: 99%

The causal relationship between the gut microbiota and acute pancreatitis: A 2-sample Mendelian randomization study

He,

Luo,

et al. 2024

Medicine

View full text Add to dashboard Cite

Several observational studies have reported a correlation between the gut microbiota (GM) and the risk of acute pancreatitis (AP). However, the causal relationship between them remains uncertain. We conducted a 2-sample Mendelian randomization (MR) study using pooled data from genome-wide association studies of 211 taxa (131 genera, 35 families, 20 orders, 16 classes, and 9 phyla) and AP patients. We evaluated the causal relationship between the GM and AP using methods such as inverse-variance weighting, MR-Egger, weighted medians, simple mode, and weighted mode. Cochran Q test, MR-Egger regression intercept analysis, and MR-PRESSO were used to examine the heterogeneity, multipotency, and outlier values of the variables, respectively. The reverse causal relationship between AP and the GM was assessed with reverse MR. In total, 5 gut microbial taxa were significantly associated with AP. The inverse-variance weighting results indicated that Acidaminococcaceae (odds ratio [OR]: 0.81, 95% confidence interval [CI]: 0.66–1.00, P = .045) and Ruminococcaceae UCG004 (OR: 0.85, 95% CI: 0.72–0.99, P = .040) were protective factors against the occurrence of AP. Coprococcus 3 (OR: 1.32, 95% CI: 1.03–1.70, P = .030), Eisenbergiella (OR: 1.13, 95% CI: 1.00–1.28, P = .043), and the Eubacterium fissicatena group (OR: 1.18, 95% CI: 1.05–1.33, P = .006) were risk factors for the development of AP. A comprehensive sensitivity analysis proved our results to be reliable. Reverse MR analysis did not indicate any causal relationship between AP and the GM. This study revealed a complex causal relationship between 5 GM taxa and AP, providing new insights into the diagnostic and therapeutic potential of the GM in AP patients.

show abstract

Section: Discussionmentioning

confidence: 99%

The causal relationship between the gut microbiota and acute pancreatitis: A 2-sample Mendelian randomization study

He,

Luo,

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…Fenofibrate plus octreotide acetate demonstrated a significantly better (P=0.037) and synergistic therapeutic effect in Chinese patients with acute hyperlipidemia pancreatitis. The combination provided a more significant anti-inflammatory effect and protected liver function leading to the improved prognosis of these patients; and has been recommended for patients with acute pancreatitis having diabetes and fatty liver simultaneously [32].…”

Section: Dyslipidemia Without High Cardiovascular Disease or As-cvd Riskmentioning

confidence: 99%

Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review

Deerochanawong,

Kim,

Chang

2024

Diabetes Metab J

View full text Add to dashboard Cite

Hypertriglyceridemia and decreased high-density lipoprotein cholesterol (HDL-C) persist despite statin therapy, contributing to residual atherosclerotic cardiovascular disease (ASCVD) risk. Asian subjects are metabolically more susceptible to hypertriglyceridemia than other ethnicities. Fenofibrate regulates hypertriglyceridemia, raises HDL-C levels, and is a recommended treatment for dyslipidemia. However, data on fenofibrate use across different Asian regions are limited. This narrative review summarizes the efficacy and safety data of fenofibrate in Asian subjects with dyslipidemia and related comorbidities (diabetes, metabolic syndrome, diabetic retinopathy, and diabetic nephropathy). Long-term fenofibrate use resulted in fewer cardiovascular (CV) events and reduced the composite of heart failure hospitalizations or CV mortality in type 2 diabetes mellitus. Fenofibrate plays a significant role in improving irisin resistance and microalbuminuria, inhibiting inflammatory responses, and reducing retinopathy incidence. Fenofibrate plus statin combination significantly reduced composite CV events risk in patients with metabolic syndrome and demonstrated decreased triglyceride and increased HDL-C levels with an acceptable safety profile in those with high CV or ASCVD risk. Nevertheless, care is necessary with fenofibrate use due to possible hepatic and renal toxicities in vulnerable individuals. Long-term trials and real-world studies are needed to confirm the clinical benefits of fenofibrate in the heterogeneous Asian population with dyslipidemia.

show abstract

“…Fenofibrate improved both HFD-induced insulin resistance in skeletal muscle and palmitic acid-induced insulin resistance in myotube cells, thus reduced ER stress-induced inflammation via inhibiting TLR4/NF-κB pathway [ 30 ]. Moreover, by activating PPAR-α, fenofibrate suppresses the NF-κB P65 pathway and renders anti-inflammatory effects in patients with acute hypertriglyceridemic pancreatitis [ 49 ]. Fenofibrate is commonly used for hyperlipidemia in clinic.…”

Section: Anti-inflammatory Mechanism Of Fenofibratementioning

confidence: 99%

“…This effect is partially linked to fenofibrate-induced reduction of lipids in the serum (Table 1). Rat, Differentiated C2C12 myotubes TLR4/NF-κB pathway↓ Reduce ER stress-induced inflammation [30] Human PPAR-α↑-NF-κB P65↓ Reduce inflammatory responses [49] PRAR-α: Peroxisome proliferator-activated receptors; AMPK: Adenosine monophosphate activated protein kinase; SIRT1: Sirtuin 1; NF-κB: Nuclear factor κB; TNF-α: Tumor necrosis factor α; MIF: Macrophage migration inhibitory factor; RANTES: Regulated upon activation, normal T cell expressed and secreted; COX-2: Cyclooxygenase-2; TLR4: Toll-like receptor-4; LPL: Lipoprotein lipase; NOD: Non-obese diabetic.…”

Section: Hyperlipidemiamentioning

confidence: 99%

Anti-inflammatory role of fenofibrate in treating diseases

Jin

et al. 2023

Biomol Biomed

View full text Add to dashboard Cite

Inflammation contributes to the pathogenesis of several diseases. Fenofibrate, known as a peroxisome proliferator-activated receptor - α (PPAR-α) agonist, is a classic drug for treating hyperlipidemia. In addition to its lipid-lowering effect, fenofibrate has also been reported to exert anti-inflammatory effects with complicated underlying mechanisms of action. In general, the anti-inflammatory effect of fenofibrate is secondary to its lipid-lowering effect, especially for the inflammation caused by hyperlipidemia in the circulatory system. Some anti-inflammatory actions may also come from its regulatory effects on intracellular lipid metabolism by activating PPAR-α. In addition, some roles in anti-inflammation might be mediated by its direct regulation of inflammatory signaling pathways. In order to understand anti-inflammatory activities and the underlying mechanisms of fenofibrate action in disease better, we herein reviewed and discussed the anti-inflammatory roles and its subserving mechanisms in various diseases of different organ systems. Thus, this review offers insights into the optimal use of fenofibrate in the clinical setting.

show abstract

PPAR-Alpha Agonist Fenofibrate Combined with Octreotide Acetate in the Treatment of Acute Hyperlipidemia Pancreatitis

Cited by 9 publications

References 30 publications

The causal relationship between the gut microbiota and acute pancreatitis: A 2-sample Mendelian randomization study

The causal relationship between the gut microbiota and acute pancreatitis: A 2-sample Mendelian randomization study

Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review

Anti-inflammatory role of fenofibrate in treating diseases

Contact Info

Product

Resources

About